234 related articles for article (PubMed ID: 27068475)
1. Activation of P-TEFb by Androgen Receptor-Regulated Enhancer RNAs in Castration-Resistant Prostate Cancer.
Zhao Y; Wang L; Ren S; Wang L; Blackburn PR; McNulty MS; Gao X; Qiao M; Vessella RL; Kohli M; Zhang J; Karnes RJ; Tindall DJ; Kim Y; MacLeod R; Ekker SC; Kang T; Sun Y; Huang H
Cell Rep; 2016 Apr; 15(3):599-610. PubMed ID: 27068475
[TBL] [Abstract][Full Text] [Related]
2. Patient-derived Hormone-naive Prostate Cancer Xenograft Models Reveal Growth Factor Receptor Bound Protein 10 as an Androgen Receptor-repressed Gene Driving the Development of Castration-resistant Prostate Cancer.
Hao J; Ci X; Xue H; Wu R; Dong X; Choi SYC; He H; Wang Y; Zhang F; Qu S; Zhang F; Haegert AM; Gout PW; Zoubeidi A; Collins C; Gleave ME; Lin D; Wang Y
Eur Urol; 2018 Jun; 73(6):949-960. PubMed ID: 29544736
[TBL] [Abstract][Full Text] [Related]
3. Global analysis of transcription in castration-resistant prostate cancer cells uncovers active enhancers and direct androgen receptor targets.
Toropainen S; Niskanen EA; Malinen M; Sutinen P; Kaikkonen MU; Palvimo JJ
Sci Rep; 2016 Sep; 6():33510. PubMed ID: 27641228
[TBL] [Abstract][Full Text] [Related]
4. Positive feedback loop mediated by protein phosphatase 1α mobilization of P-TEFb and basal CDK1 drives androgen receptor in prostate cancer.
Liu X; Gao Y; Ye H; Gerrin S; Ma F; Wu Y; Zhang T; Russo J; Cai C; Yuan X; Liu J; Chen S; Balk SP
Nucleic Acids Res; 2017 Apr; 45(7):3738-3751. PubMed ID: 28062857
[TBL] [Abstract][Full Text] [Related]
5. Lipocalin 2 over-expression facilitates progress of castration-resistant prostate cancer via improving androgen receptor transcriptional activity.
Ding G; Wang J; Feng C; Jiang H; Xu J; Ding Q
Oncotarget; 2016 Sep; 7(39):64309-64317. PubMed ID: 27602760
[TBL] [Abstract][Full Text] [Related]
6. Nucleoporin 62 and Ca(2+)/calmodulin dependent kinase kinase 2 regulate androgen receptor activity in castrate resistant prostate cancer cells.
Karacosta LG; Kuroski LA; Hofmann WA; Azabdaftari G; Mastri M; Gocher AM; Dai S; Hoste AJ; Edelman AM
Prostate; 2016 Feb; 76(3):294-306. PubMed ID: 26552607
[TBL] [Abstract][Full Text] [Related]
7. Steroidogenic enzyme AKR1C3 is a novel androgen receptor-selective coactivator that promotes prostate cancer growth.
Yepuru M; Wu Z; Kulkarni A; Yin F; Barrett CM; Kim J; Steiner MS; Miller DD; Dalton JT; Narayanan R
Clin Cancer Res; 2013 Oct; 19(20):5613-25. PubMed ID: 23995860
[TBL] [Abstract][Full Text] [Related]
8. Regulation of the transcriptional coactivator FHL2 licenses activation of the androgen receptor in castrate-resistant prostate cancer.
McGrath MJ; Binge LC; Sriratana A; Wang H; Robinson PA; Pook D; Fedele CG; Brown S; Dyson JM; Cottle DL; Cowling BS; Niranjan B; Risbridger GP; Mitchell CA
Cancer Res; 2013 Aug; 73(16):5066-79. PubMed ID: 23801747
[TBL] [Abstract][Full Text] [Related]
9. Coregulator recruitment and histone modifications in transcriptional regulation by the androgen receptor.
Kang Z; Jänne OA; Palvimo JJ
Mol Endocrinol; 2004 Nov; 18(11):2633-48. PubMed ID: 15308689
[TBL] [Abstract][Full Text] [Related]
10. Phosphorylation of the androgen receptor at Ser81 is co-sustained by CDK1 and CDK9 and leads to AR-mediated transactivation in prostate cancer.
Gao X; Liang J; Wang L; Zhang Z; Yuan P; Wang J; Gao Y; Ma F; Calagua C; Ye H; Voznesensky O; Wang S; Wang T; Liu J; Chen S; Liu X
Mol Oncol; 2021 Jul; 15(7):1901-1920. PubMed ID: 33932081
[TBL] [Abstract][Full Text] [Related]
11. Downregulation of androgen receptors by NaAsO
Kim Y; Park SE; Moon JW; Kim BM; Kim HG; Jeong IG; Yoo S; Ahn JB; You D; Pak JH; Kim S; Hwang JJ; Kim CS
Prostate; 2017 Jul; 77(10):1128-1136. PubMed ID: 28556958
[TBL] [Abstract][Full Text] [Related]
12. Hydrazinobenzoylcurcumin inhibits androgen receptor activity and growth of castration-resistant prostate cancer in mice.
Wu M; Kim SH; Datta I; Levin A; Dyson G; Li J; Kaypee S; Swamy MM; Gupta N; Kwon HJ; Menon M; Kundu TK; Reddy GP
Oncotarget; 2015 Mar; 6(8):6136-50. PubMed ID: 25704883
[TBL] [Abstract][Full Text] [Related]
13. Identification of a negative regulatory cis-element in the enhancer core region of the prostate-specific antigen promoter: implications for intersection of androgen receptor and nuclear factor-kappaB signalling in prostate cancer cells.
Cinar B; Yeung F; Konaka H; Mayo MW; Freeman MR; Zhau HE; Chung LW
Biochem J; 2004 Apr; 379(Pt 2):421-31. PubMed ID: 14715080
[TBL] [Abstract][Full Text] [Related]
14. Arrestin2 modulates androgen receptor activation.
Purayil HT; Zhang Y; Dey A; Gersey Z; Espana-Serrano L; Daaka Y
Oncogene; 2015 Jun; 34(24):3144-51. PubMed ID: 25109335
[TBL] [Abstract][Full Text] [Related]
15. SRRM4 Expression and the Loss of REST Activity May Promote the Emergence of the Neuroendocrine Phenotype in Castration-Resistant Prostate Cancer.
Zhang X; Coleman IM; Brown LG; True LD; Kollath L; Lucas JM; Lam HM; Dumpit R; Corey E; Chéry L; Lakely B; Higano CS; Montgomery B; Roudier M; Lange PH; Nelson PS; Vessella RL; Morrissey C
Clin Cancer Res; 2015 Oct; 21(20):4698-708. PubMed ID: 26071481
[TBL] [Abstract][Full Text] [Related]
16. The role of TXNDC5 in castration-resistant prostate cancer-involvement of androgen receptor signaling pathway.
Wang L; Song G; Chang X; Tan W; Pan J; Zhu X; Liu Z; Qi M; Yu J; Han B
Oncogene; 2015 Sep; 34(36):4735-45. PubMed ID: 25500540
[TBL] [Abstract][Full Text] [Related]
17. Androgen receptors in hormone-dependent and castration-resistant prostate cancer.
Shafi AA; Yen AE; Weigel NL
Pharmacol Ther; 2013 Dec; 140(3):223-38. PubMed ID: 23859952
[TBL] [Abstract][Full Text] [Related]
18. Non-Coding RNAs in Castration-Resistant Prostate Cancer: Regulation of Androgen Receptor Signaling and Cancer Metabolism.
Shih JW; Wang LY; Hung CL; Kung HJ; Hsieh CL
Int J Mol Sci; 2015 Dec; 16(12):28943-78. PubMed ID: 26690121
[TBL] [Abstract][Full Text] [Related]
19. Enhancer RNAs participate in androgen receptor-driven looping that selectively enhances gene activation.
Hsieh CL; Fei T; Chen Y; Li T; Gao Y; Wang X; Sun T; Sweeney CJ; Lee GS; Chen S; Balk SP; Liu XS; Brown M; Kantoff PW
Proc Natl Acad Sci U S A; 2014 May; 111(20):7319-24. PubMed ID: 24778216
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of LSD1 by Pargyline inhibited process of EMT and delayed progression of prostate cancer in vivo.
Wang M; Liu X; Guo J; Weng X; Jiang G; Wang Z; He L
Biochem Biophys Res Commun; 2015 Nov; 467(2):310-5. PubMed ID: 26435505
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]